Enovis (NYSE:ENOV) Stock Price Up 4.6% – Here’s Why

Enovis Corporation (NYSE:ENOV)’s stock price shot up 4.6% on Tuesday . The company traded as high as $25.78 and last traded at $25.87. Approximately 60,484 shares changed hands during trading, a decline of 95% from the average session volume of 1,100,257 shares. The stock had previously closed at $24.74.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ENOV shares. BMO Capital Markets reiterated an “outperform” rating and issued a $30.00 price objective on shares of Enovis in a report on Friday, August 7th. Evercore set a $32.00 target price on shares of Enovis in a report on Monday, July 6th. BTIG Research raised their target price on shares of Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Canaccord Genuity Group lowered their price target on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.29.

Enovis Price Performance

The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -1.34 and a beta of 1.34. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The company has a 50-day simple moving average of $24.91 and a two-hundred day simple moving average of $24.05.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. During the same period in the previous year, the company earned $0.79 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts forecast that Enovis Corporation will post 3.12 EPS for the current year.

Insider Activity at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 4,200 shares of company stock valued at $92,084. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Hedge funds have recently bought and sold shares of the company. Impax Asset Management Group plc increased its position in Enovis by 36.5% during the fourth quarter. Impax Asset Management Group plc now owns 424,130 shares of the company’s stock worth $11,299,000 after buying an additional 113,500 shares during the last quarter. Bernzott Capital Advisors lifted its position in shares of Enovis by 47.4% in the first quarter. Bernzott Capital Advisors now owns 294,125 shares of the company’s stock valued at $6,691,000 after buying an additional 94,529 shares during the last quarter. Front Street Capital Management Inc. boosted its stake in shares of Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares during the period. Invenomic Capital Management LP boosted its stake in shares of Enovis by 6.2% during the 4th quarter. Invenomic Capital Management LP now owns 756,717 shares of the company’s stock worth $20,159,000 after acquiring an additional 44,048 shares during the period. Finally, Fifth Third Bancorp boosted its stake in shares of Enovis by 50,442.8% during the 1st quarter. Fifth Third Bancorp now owns 83,901 shares of the company’s stock worth $1,909,000 after acquiring an additional 83,735 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.